Treatment Strategies for MSI-H/dMMR Metastatic Colorectal Cancer
[1]. 20% , [2]. 5-fluorouracil (5-FU) capecitabine fluoropyrimidine , irinotecan oxaliplatin . 2000 bevacizumab cetuximab/panitumumab . , . 5 20% [2,3]. .KEYNOTE-177 , programmed death-1 (PD-1) pembrolizumab mic-rosatellite instability-high (MSI-H) mismatch repair-deficient (dMMR) (progression-free survival, PFS) 16.5 8.2 [4]. nivolumab + ipilimumab 2 . 1 (nivolumab ipilimumab) 3
Authors
- Hun Ho Song
- Jiyoung Yoon (ORCID: https://orcid.org/0000-0001-7448-4296)
Institutions
- Hallym University (KR)
- Kangdong Sacred Heart Hospital (KR)
Publication Details
- Journal
- Journal of Digestive Cancer Research
- Published
- 2025-04-18
- DOI
- https://doi.org/10.52927/jdcr.2025.13.1.86
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00